Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
International Journal of Cardiovascular Sciences · 2020
DOI: 10.36660/ijcs.20190141 ↗At a glance
Journal article in International Journal of Cardiovascular Sciences, 2020. Written by Rita Carolina Figueiredo Duarte and 10 co-authors. Cited 1 times so far (Crossref); 16 references.
Abstract (original language)
Background
Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor.
Objectives
This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture.
Methods
We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant.
Results
An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT / INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose.
Conclusion
We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0
Cite
APA
Duarte, R. C. F., Moreira, P. S. S., Ferreira, C. N., Figueiredo, E. L., Sternick, E., Silveira, F. R., Alves, L. C. V., Mota, A. P. L., Reis, E. A., Carvalho, M. D. G., & Reis, H. J. D. (2020). Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection. International Journal of Cardiovascular Sciences. https://doi.org/10.36660/ijcs.20190141
Vancouver
Duarte RCF, Moreira PSS, Ferreira CN, Figueiredo EL, Sternick E, Silveira FR, et al. Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection. International Journal of Cardiovascular Sciences. 2020. doi:10.36660/ijcs.20190141
BibTeX
@article{Duarte2020,
author = {Duarte, Rita Carolina Figueiredo and Moreira, Priscila Samara Sérgio and Ferreira, Cláudia Natália and Figueiredo, Estevão Lanna and Sternick, Eduardo and Silveira, Francisco Rezende and Alves, Luan Carlos Vieira and Mota, Ana Paula Lucas and Reis, Edna Afonso and Carvalho, Maria das Graças and Reis, Helton José dos},
title = {Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection},
journal = {International Journal of Cardiovascular Sciences},
year = {2020},
doi = {10.36660/ijcs.20190141}
}
EUVIMED